Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

Bibliographic Details
Main Authors:	Chowdhury, O, O’Sullivan, J, Barkas, N, Wang, G, Buck, G, Hamblin, A
Format:	Journal article
Language:	English
Published:	Springer Nature 2020

Similar Items

Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
by: Chowdhury, O, et al.
Published: (2018)

Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
by: Bing Li, et al.
Published: (2017-05-01)

Mechanisms of disease transformation in myeloproliferative neoplasms
by: O'Sullivan, J
Published: (2022)

Heterogeneity in myeloproliferative neoplasms: causes and consequences
by: O'Sullivan, J, et al.
Published: (2018)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
by: Gowin KL, et al.
Published: (2015-04-01)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
by: Butt, N, et al.
Published: (2019)

Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms
by: Luca Malcovati, et al.
Published: (2014-11-01)

Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors
by: Tiziano Barbui, et al.
Published: (2024-10-01)

TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche
by: Juo-Chin Yao, et al.
Published: (2022-06-01)

Single-cell methods in myeloproliferative neoplasms: old questions, new technologies
by: O'Sullivan, JM, et al.
Published: (2023)

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
by: Jean-Christophe Ianotto, et al.
Published: (2018-03-01)

Ph-negative chronic myeloproliferative neoplasm (primary myelofibrosis)– as one of the reasons of the Budd-Chiari syndrome.
by: Maria Dmitrievna Sanatko
Published: (2012-06-01)

Ph-negative chronic myeloproliferative neoplasm (primary myelofibrosis)– as one of the reasons of the Budd-Chiari syndrome.
by: Maria Dmitrievna Sanatko
Published: (2012-01-01)

Mutations in the miR-142 gene are not common in myeloproliferative neoplasms
by: Paulina Galka-Marciniak, et al.
Published: (2022-06-01)

Evaluation of Common Genetic Disorders in Myeloproliferative Neoplasms
by: Mehrdad Payandeh, et al.
Published: (2011-09-01)

Evaluation of Common Genetic Disorders in Myeloproliferative Neoplasms
by: Hoshang Yousefi, et al.
Published: (2011-10-01)

CALR Mutations in Myeloproliferative Neoplasms
by: Ken-Hong Lim
Published: (2014-06-01)

Myelodysplastic syndrome/myeloproliferative neoplasm – ring sideroblast with myelofibrosis – A diagnostic dilemma/? A distinct entity
by: Amandeep Talwar, et al.
Published: (2021-01-01)

Myeloproliferative neoplasms
by: Nick Cross, (Coordinating Author)
Published: (2019-06-01)

Myeloproliferative neoplasms
by: Jean-Jacques Kiladjian
Published: (2018-06-01)

A Case of Philadelphia Chromosome Positive Myeloproliferative Neoplasm in a Pregnant Woman with Unusual Primary Myelofibrosis Features
by: Jason Koshy, et al.
Published: (2013-01-01)

Epigenetics and mutations in chronic myeloproliferative neoplasms
by: Alessandro M. Vannucchi, et al.
Published: (2011-10-01)

Functional Consequences of Mutations in Myeloproliferative Neoplasms
by: Stefan N. Constantinescu, et al.
Published: (2021-06-01)

Mutations, inflammation and phenotype of myeloproliferative neoplasms
by: Sylvie Hermouet, et al.
Published: (2023-05-01)

RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort
by: O'Sullivan, JM, et al.
Published: (2023)

The microenvironment in myeloproliferative neoplasm
by: Simón Méndez-Ferrer, et al.
Published: (2018-06-01)

Spleen in myeloproliferative neoplasms
by: Giovanni Barosi
Published: (2018-06-01)

Epigenetics in myeloproliferative neoplasms
by: Graeme Greenfield, et al.
Published: (2023-07-01)

Treatment of Myeloproliferative Neoplasms With Janus Kinase Inhibitors: A Meta‐Analysis of Cardiovascular Safety
by: Roberta Dunn, et al.
Published: (2025-02-01)

Myelodysplastic/Myeloproliferative Neoplasms with Features Intermediate between Primary Myelofibrosis and Chronic Myelomonocytic Leukemia: Case Series and Review of the Entity
by: Arturo Bonometti, et al.
Published: (2024-07-01)

JAK1 somatic mutation in a myeloproliferative neoplasm
by: Suzanne O. Arulogun, et al.
Published: (2017-08-01)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
by: Ziqi Wan, et al.
Published: (2020-10-01)

Impact of mutations on pregnancy outcome in patients with myeloproliferative neoplasms
by: Dawn Maze, et al.
Published: (2023-02-01)

Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms
by: Thomas Ernst, et al.
Published: (2010-09-01)

FREQUENCY OF CALR GENE MUTATION IN MYELOPROLIFERATIVE NEOPLASMS
by: Sana Latif, et al.
Published: (2020-04-01)

Classification and personalized prognosis in myeloproliferative neoplasms
by: Grinfeld, J, et al.
Published: (2018)

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
by: Shivam Rai, et al.
Published: (2022-09-01)

Myeloproliferative neoplasm stem cells
by: Mead, A, et al.
Published: (2017)

The Hematopoietic Niche in Myeloproliferative Neoplasms
by: Annette H. Schmitt-Graeff, et al.
Published: (2015-01-01)

Pathophysiology of thrombosis in myeloproliferative neoplasms
by: Raffaele Landolfi, et al.
Published: (2011-02-01)